BackSanten Pharmaceutical , Ltd. Overview

Santen Pharmaceutical , Ltd. Long Term Debt

Track Santen Pharmaceutical , Ltd.'s long-term debt ($31B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$30.78B

Peer trimmed avg / median

Loading

Santen Pharmaceutical , Ltd. Long Term Debt History

Loading

Santen Pharmaceutical , Ltd. vs. peers: Long Term Debt Comparison

Loading

Santen Pharmaceutical , Ltd. Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Santen Pharmaceutical , Ltd. (SNPHY) FAQ

As of the most recent data (June 2026), SNPHY shows a long-term debt of $31B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SNPHY's long-term debt is now $31B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Santen Pharmaceutical , Ltd. is outperforming or lagging.

Tracking SNPHY's long-term debt over time shows whether Santen Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $31B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Santen Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $31B) with ownership activity and broader fundamentals.